Krenitsky, Amanda
Klager, Skylar
Hatch, Leigh
Sarriera-Lazaro, Carlos
Chen, Pei Ling
Seminario-Vidal, Lucia
Article History
Accepted: 10 May 2022
First Online: 19 July 2022
Declarations
:
: No external funding was used in the preparation of this article.
: LSV is currently an employee and shareholder of Eli Lily and Company. LSV had advisory board relationships with Novartis, Boehringer Ingelheim, Helsinn, Kyowa Kirin, Regeneron, and Blueprint. She or her institution received research funding from Eli Lilly and Company, Soligenix, Helsinn, Eisai, Boehringer Ingelheim, Novartis, AbbVie, BMS, Celgene, Glenmark, Kyowa Kirin, Amgen, AnaptysBio, and Innate Pharma. LSV has been a speaker for Helsinn and Kyowa Kirin. These disclosures are not relevant to the current article. The rest of the authors have no conflicts of interest to declare.
: Not applicable.
: Not applicable.
: Photo consent was obtained for all clinical photos included within this article.
: Not applicable.
: Not applicable.
: A.K., S.K., and L.H. drafted the manuscript. C.L.S., P.L.C., and L.S.V. provided important input. P.L.C. and L.S.V. supervised the process. All authors reviewed and edited the final version.
Free to read: This content has been made available to all.